Strategic biopharmaceutical portfolio development: An analysis of constraint-induced implications

Biotechnology Progress

Volumn 24, Issue 3, 2008, Pages 698-713

  George, Edmund D ^a   Farid, Suzanne S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AEROSPACE APPLICATIONS; ARCHITECTURAL DESIGN; ARTIFICIAL INTELLIGENCE; BAYESIAN NETWORKS; CHEMOTHERAPY; COMPUTER NETWORKS; DECISION MAKING; DRUG DELIVERY; DRUG DOSAGE; DRUG THERAPY; ENGINEERS; FINANCE; INFERENCE ENGINES; LEARNING SYSTEMS; MANUFACTURE; METROPOLITAN AREA NETWORKS; MULTIOBJECTIVE OPTIMIZATION; NETWORK PROTOCOLS; OPTIMIZATION; PROBABILITY; RISK ASSESSMENT; SET THEORY; STRATEGIC PLANNING;

AMERICAN CHEMICAL SOCIETY (ACS); AMERICAN INSTITUTE OF CHEMICAL ENGINEERS (AICHE); BAYESIAN; CASE STUDIES; CASH FLOWS; CRITICAL ACTIVITIES; MACHINE-LEARNING; MULTI OBJECTIVE OPTIMIZATION (MOP); MULTI OBJECTIVES; OBJECTIVE SPACES; OPTIMALITY; PORTFOLIO DEVELOPMENT; PROBABILISTIC STRUCTURES; PROBABILITY OF SUCCESS; STRATEGIC DECISIONS; THIRD PARTIES; UNCERTAIN ENVIRONMENTS;

PLANNING;

DRUG;

CONFERENCE PAPER; DRUG INDUSTRY; ECONOMICS; PHARMACEUTICS; STATISTICAL MODEL; UNITED KINGDOM;

BIOPHARMACEUTICS; DRUG INDUSTRY; GREAT BRITAIN; MODELS, ECONOMIC; PHARMACEUTICAL PREPARATIONS;

EID: 45149109818     PISSN: 87567938     EISSN: None     Source Type: Journal    
DOI: 10.1021/bp070410s     Document Type: Conference Paper

References (49)

1. Ashton, G. Growing pains for biopharmaceuticals. Nat. Biotechnol. 2001, 10, 307-311.
2. Blau, G.; Mehta, B.; Bose, S.; Penky, J.; Sinclair, G.; Keunker, K.; Bunch, P. Risk management in development of new products in highly regulated industries. Comput. Chem. Eng. 2000, 24, 2211-2222.
3. Blau, G. E.; Penky, J. F.; Varma, V. A.; Bunch P. R. Managing a portfolio of independent new product candidates in the pharmaceutical industry. J. Prod. Innovation Manage. 2004, 21, 27-245.
4. Boston Consulting Group. A Revolution in R&D: How Genomics and Genetics are Transforming the Biopharmaceutical Industry. Boston Consulting Group: Boston, MA, 2001).
5. Buntine, W. L. Theory and refinement of Bayesian networks. In Proceedings of Seventh Conference on Uncertainty in Artificial Intelligence; Morgan Kauffmann: Los Angeles, CA, 1991; pp 52-60.
6. Choi, J.; Realff, M. J.; Lee, J. H. Dynamic programming in a heuristically confined state space: A stochastic resource-constrained project scheduling application. Comput. Chem. Eng. 2004, 28 (6-7), 1039-1058.
7. Colvin, M.; Maravelias, C. T. A stochastic programming approach for clinical trial planning in new drug development. Comput. Chem. Eng. 2008, doi: 10.1016/j.compchemeng.2007.11.010.
8. DiMasi, J.; Hansen, R. W.; Gabrowski, H. G. The price of innovation: new estimates of drug development costs. J. Health Econ. 2003, 22, 151-185.
9. Farid, S.; Washbrook, J.; Titchener-Hooker, N. J. Decision-support tool for assessing biomanufacturing strategies under uncertainty: stainless steel versus disposable equipment for clinical trial material preparation. Biotechnol. Prog. 2005a, 21 (2), 486-497.
10. Farid, S. S.; Washbrook, J.; Titchener-Hooker, N. J. Combining multiple quantitative and qualitative goals when assessing biomanufacturing strategies under uncertainty. Biotechnol. Prog. 2005b, 21 (4), 1183-1191.
11. Farid, S. S.; Washbrook, J.; Titchener-Hooker, N. J. Modelling biopharmaceutical manufacture: Design and implementation of SimBiopharma. Comput. Chem. Eng. 2007, 31 (9), 1141-1158.
12. Finnegan, S.; Pinto, K. Offshoring: the globalization of outsourced bioprocessing. BioProcess Int. 2006, 4 (8), S56-S62.
13. Foo, F.; Karri, S.; Titchener-Hooker, N.; Dunnill, P. Biopharmaceutical process development: part 1, information from the first product generation. Biopharm Eur. 2001, 13, 58-64.
14. Gatica, G.; Papageorgiou, L. G.; Shah, N. Capacity planning under uncertainty for the pharmaceutical industry. Trans. Inst. Chem. Eng. 2003, 81 (A), 665-667.
15. George, E. D.; Titchener-Hooker, N. J.; Farid, S. S. A multi-criteria decision-making framework for the selection of strategies for acquiring biopharmaceutical manufacturing capacity. Comput. Chem. Eng. 2007, 31 (8), 889-901.
16. Getz, K. The expanding outside clinical services contractor marketplace. Clin. Res. Regul. Affairs 1997, 14 (3 and 4), 243-254.
17. Goldberg, D. E. Genetic Algorithms in Search, Optimization, and Machine Learning. Addison-Wesley: Reading, MA, 1989.
18. Heckerman, D.; Geiger, D.; Chickering, D. M. Learning Bayesian networks: A combination of knowledge and statistical data. Mach. Learn. 1995, 20, 197-243.
19. Harik, G. R.; Lobo, F.; Goldberg, D. The compact genetic algorithm. IEEE Trans. Evol. Comput. 1999, 3 (4), 287-297.
20. Holland, J. H. Adaptation in Natural and Artificial Systems; University of Michigan Press: Ann Arbor, 1975.
21. Jain, V.; Grossmann, I. E. Resource-constrained scheduling of tests in new product development. Ind. Eng. Chem. Res. 1999, 38, 3013-3026.
22. Lakhdar, K.; Zhou, Y.; Savery, J.; Titchener-Hooker, N. J.; Papageorgiou, L. G. Medium term planning of biopharmaceutical manufacture using mathematical programming. Biotechnol. Prog. 2005, 21, 1478-1489.
23. Levis, A. A.; Papageorgiou, L. G. A hierarchical solution approach for multi-site capacity planning under uncertainty in the pharmaceutical industry. Comput. Chem. Eng. 2004, 28, 707-725.
24. Lim, A. C.; Zhou, Y.; Washbrook, J.; Sinclair, A.; Fish, B.; Francis, R.; Titchener-Hooker, N. J.; Farid, S. S. Application of a decision-support tool to assess pooling strategies in perfusion culture processes under uncertainty. Biotechnol. Prog. 2005a, 21 (4), 1231-1242.
25. Lim, A. C.; Washbrook, J.; Titchener-Hooker, N. J.; Farid, S. S. A computer-aided approach to compare the production economics of fed-batch and perfusion culture under uncertainty. Biotechnol. Bioeng. 2005b, 93 (4), 687-697.
26. MacQueen, J. B. Some methods for classification and analysis of multivariate observations. Proceeding of the 5th Symposium on Mathematics, Statistics, and Probability; University of California Press: Berkeley, 1967; pp 281-297.
27. Matsumoto, M.; Nishimura, T. Mersenne Twister: A 623 dimensionally equidistributed uniform pseudo-random number generator. ACM Trans. Model. Comput. Simul. 1998, 8(1), 3-30.
28. Maravelias, C. T.; Grossman, I. E. Simultaneous planning for new product development and batch manufacturing facilities. Ind. Eng. Chem. Res. 2001, 40, 6147-6164.
29. Mühlenbein, H.; Paass, G. From recombination of genes to the estimation of distributions I. Binary Parameters. Parallel Problem Solving from Nature, PPSN 1996, IV, 178-187.
30. Mühlenbein, H. The equation for response to selection and its use for prediction. Evol. Comput. 1997, 5(3), 303-346.
31. Neapolitan, R. E. Learning Bayesian Networks; Prentice Hall: Upper Saddle River, NJ, 2003.
32. Nicholson, S.; Danzon, P. M.; McCullough, J. Biotech-pharmaceutical alliances as a signal of asset firm and quality. J. Business 2005, 78 (4), 1433-1464.
33. Oh, H.; Karimi, I. A. Regulatory factors and capacity-expansion planning in global chemical supply chains. Ind. Eng. Chem. Res. 2004, 43, 3364-3380.
34. Papageorgiou, L. G.; Rotstein, G. E.; Shah, N. Strategic supply chain optimization for the pharmaceutical industries. Ind. Eng. Chem. Res. 2001, 40, 275-286.
35. Pelikan, M.; Goldberg, D.; Lobo, F. A survey of optimizations by building and using probabilistic models. Comput. Optim. Appl. 2000, 21, 5-20.
36. Pelikan, M.; Goldberg, D.; Cantú-Paz, E. Linkage problem, Distribution estimation, and Bayesian networks. Evol. Comput. 2000, 8 (3), 311-340.
37. Pelikan, M.; Sastry, K.; Goldberg, D. E. Multiobjective hBOA, clustering, and scalability. Proceedings of the 2005 Conference on Genetic and Evolutionary Computation, Washington, DC, 2005; pp 663-670.
38. Piachaud, B. S. Outsourcing in the pharmaceutical manufacturing process: an examination of the CRO experience. Technovation 2002, 22, 81-90.
39. Rakapakse, A.; Titchener-Hooker, N. J.; Farid, S. S. Modelling of the biopharmaceutical drug development pathway and portfolio management. Comput. Chem. Eng. 2005, 29, 1357-1368.
40. Rakapakse, A.; Titchener-Hooker, N. J.; Farid, S. S. Integrated approach to improving the value potential of biopharmaceutical R&D portfolios while mitigating risk. J. Chem. Technol. Biochem. Technol. 2006, 81, 1705-1714.
41. Reichert, J. M. Trends in development and approval for new therapeutics in the Untied States. Nat. Drug Discovery 2003, 2, 695-702.
42. Rogers, M. J.; Gupta, A.; Maranas, C. D. Real options based analysis of optimal pharmaceutical research and development portfolios. Ind. and Eng. Chem. Res. 2002, 41, 6607-6620.
43. Rogers, M. J.; Maranas, C. D. Valuation and design of pharmaceutical R&D licensing deals. AIChE J. 2005, 51(1), 198-209.
44. Subramanian, D.; Penky, J. F.; Reklaitis, G. V. A simulation-optimization framework fir research and development pipeline management. AIChE J. 2001, 47, 2226-2242.
45. Subramanian, D.; Penky, J. F.; Reklaitis, G. V.; Blau, G. E. Simulation-optimization framework for stochastic optmization of R&D pipeline management. Process Syst. Eng. 2003, 49 (1), 96-112.
46. Triantaphyllou, E. Multi-criteria Decision Making Methods: A Comparative Study; Kluwer Academic Publishers: Dordrecht, The Netherlands, 2000.
47. Varma, V. A.; Pekny, J. F.; Blau, G. E.; Reklaitis, G. V. A framework for addressing stochastic and combinatorial aspects of scheduling and resource allocation inpharmaceutical R&D pipelines. Comput. Chem. Eng. 2008, doi: 10.1016/j.compchemeng.2007.05.006.
48. Werner, R. G. Economic aspects of commercial manufacture of biopharmaceuticals. J. Biotechnol. 2004, 113, 171-182.
49. Yang S.; Chang, K. Comparison of score metrics for Bayesian network learning. IEEE Trans. Systems, Man, Cybernet., Part A 2002, 32 (3), 419-428.